• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (7)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Ocular/ Adnexal Tumors  • Pediatric Ophthalmology  • Retinal/ Chorioretinal Disorders  • Vitreoretinal Surgery  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Shin J. Kang, MD; Chandrasekar Durairaj, PhD; Uday B. Kompella, PhD; Joan M. O’Brien, MD; Hans E. Grossniklaus, MD, MBA

Arch Ophthalmol. 2009;127(8):1043-1047.

Objective  To evaluate the efficacy of subconjunctival nanoparticle carboplatin in the treatment of transgenic murine retinoblastoma.

Methods  Dendrimeric nanoparticles loaded with carboplatin were prepared. Forty LHβ-Tag mice were randomly assigned into 4 groups and treated at 10 weeks of age. Each mouse received a single subconjunctival injection in one eye, and the opposite eye was left untreated as a control. Group 1 (high-dose nanoparticle carboplatin) received 37.5 mg/mL of nanoparticle carboplatin; group 2 (low-dose nanoparticle carboplatin) received 10 mg/mL of nanoparticle carboplatin; group 3 (conventional carboplatin) received 10 mg/mL of carboplatin in aqueous solution; and group 4 (phosphate-buffered saline) received phosphate-buffered saline. Mice were killed on day 22 after treatment. Eyes were serially sectioned, and retinal tumor burden was quantified by histopathologic analysis.

Results  Mean tumor burden in the treated eyes was significantly smaller compared with the untreated eyes in the same mice in both nanoparticle carboplatin groups (group 1, P = .02; group 2, P = .02) and the treated eyes in the conventional carboplatin group (group 1 vs group 3, P < .01; group 2 vs group 3, P = .01) and phosphate-buffered saline group (group 1 vs group 4, P < .01; group 2 vs group 4, P = .01). The untreated eyes in the high-dose nanoparticle carboplatin group showed significantly smaller tumor mass compared with the conventional carboplatin (P = .03) and PBS (P = .04) groups. No toxic effects were observed in any of the groups.

Conclusion  A single injection of subconjunctival nanoparticle carboplatin was effective in the treatment of transgenic murine retinoblastoma, with no associated toxic effects. The higher dose of subconjunctival nanoparticle carboplatin decreased the tumor burden in the contralateral eye.

Clinical Relevance  This model provides a basis to test carboplatin nanoparticles for the treatment of human retinoblastoma.

Author Affiliations: Department of Ophthalmology, Emory Eye Center, Emory University, Atlanta, Georgia (Drs Kang and Grossniklaus); University of Colorado Denver, Aurora (Drs Durairaj and Kompella); and Department of Ophthalmology, University of California, San Francisco (Dr O’Brien).

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Periocular carboplatin for retinoblastoma: long-term report (12 years) on efficacy and toxicity
Marr et al.
Br J Ophthalmol 2012;0:bjophthalmol-2011-300517v-bjophthalmol-2011-300517.
ABSTRACT | FULL TEXT  

The TAg-RB Murine Retinoblastoma Cell of Origin Has Immunohistochemical Features of Differentiated Muller Glia with Progenitor Properties
Pajovic et al.
IOVS 2011;52:7618-7624.
ABSTRACT | FULL TEXT  

Nanosized Dendritic Polyguanidilyated Translocators for Enhanced Solubility, Permeability, and Delivery of Gatifloxacin
Durairaj et al.
IOVS 2010;51:5804-5816.
ABSTRACT | FULL TEXT